Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)
South Korea · Delayed Price · Currency is KRW 6,470.00
+150.00 (2.37%)
At close: Feb 26, 2026
Seoulin Bioscience Market Cap
Seoulin Bioscience has a market cap or net worth of 58.08 billion as of February 27, 2026. Its market cap has increased by 0.13% in one year.
Market Cap
58.08B
Enterprise Value
38.32B
Revenue
76.74B
Ranking
n/a
PE Ratio
29.57
Stock Price
6,470.00
Market Cap Chart
Since October 25, 2005, Seoulin Bioscience's market cap has decreased from 69.74B to 58.08B, a decrease of -16.72%. That is a compound annual growth rate of -0.90%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 27, 2026 | 58.08B | 1.08% |
| Dec 30, 2025 | 57.46B | -6.51% |
| Dec 30, 2024 | 61.46B | -21.97% |
| Dec 28, 2023 | 78.77B | -19.25% |
| Dec 29, 2022 | 97.55B | -44.18% |
| Dec 30, 2021 | 174.75B | 62.58% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Dx & Vx | 474.43B |
| 3billion | 458.95B |
| Cytogen | 126.42B |
| GENINUS | 112.56B |
| HLB Panagene | 90.85B |
| Green Cross Medical Science | 82.51B |
| Protia | 67.09B |
| GeneMatrix | 47.01B |